Perlmutter Cancer Center

The purpose of the study is to assess safety, tolerability, and antitumor activity of DRP-104 administered via intravenous infusion as a single agent and in combination with atezolizumab in patients with advanced solid tumors. DRP-104 for Injection (40 mg/vial) drug product for intravenous administration is provided as a powder in the form of a lyophilized cake. The study drug DRP-104 is investigational, which means that it has not been approvedby the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.